Why biotech revenue projections ‘won’t look as sunny’ once Trump tax bill hits Medicaid enrollment

Insurance coverage losses caused by the Trump administration’s tax and spend law could make it harder for biotechs to secure funding and recruit patients for trials, experts have told Fierce.